These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28179403)

  • 1. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
    Alves E; Salman AM; Leoratti F; Lopez-Camacho C; Viveros-Sandoval ME; Lall A; El-Turabi A; Bachmann MF; Hill AV; Janse CJ; Khan SM; Reyes-Sandoval A
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited genetic diversity in the global Plasmodium vivax Cell traversal protein of Ookinetes and Sporozoites (CelTOS) sequences; implications for PvCelTOS-based vaccine development.
    Mehrizi AA; Torabi F; Zakeri S; Djadid ND
    Infect Genet Evol; 2017 Sep; 53():239-247. PubMed ID: 28600217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
    Bauza K; Malinauskas T; Pfander C; Anar B; Jones EY; Billker O; Hill AV; Reyes-Sandoval A
    Infect Immun; 2014 Mar; 82(3):1277-86. PubMed ID: 24379295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.
    Espinosa DA; Vega-Rodriguez J; Flores-Garcia Y; Noe AR; Muñoz C; Coleman R; Bruck T; Haney K; Stevens A; Retallack D; Allen J; Vedvick TS; Fox CB; Reed SG; Howard RF; Salman AM; Janse CJ; Khan SM; Zavala F; Gutierrez GM
    Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
    Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.
    Atcheson E; Bauza K; Salman AM; Alves E; Blight J; Viveros-Sandoval ME; Janse CJ; Khan SM; Hill AVS; Reyes-Sandoval A
    Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29986894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
    Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
    Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
    de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
    Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.
    Bergmann-Leitner ES; Legler PM; Savranskaya T; Ockenhouse CF; Angov E
    Vaccine; 2011 Aug; 29(35):5940-9. PubMed ID: 21722682
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Rodrigues-da-Silva RN; Soares IF; Lopez-Camacho C; Martins da Silva JH; Perce-da-Silva DS; Têva A; Ramos Franco AM; Pinheiro FG; Chaves LB; Pratt-Riccio LR; Reyes-Sandoval A; Banic DM; Lima-Junior JD
    Front Immunol; 2017; 8():77. PubMed ID: 28223984
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Arévalo-Pinzón G; Garzón-Ospina D; Pulido FA; Bermúdez M; Forero-Rodríguez J; Rodríguez-Mesa XM; Reyes-Guarín LP; Suárez CF; Patarroyo MA
    Front Cell Infect Microbiol; 2020; 10():119. PubMed ID: 32266169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver-Directed AAV8 Booster Vaccine Expressing
    Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
    Front Immunol; 2021; 12():612910. PubMed ID: 34248928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.
    Fonseca JA; McCaffery JN; Caceres J; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
    Vaccine; 2018 May; 36(20):2799-2808. PubMed ID: 29657070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of
    Matos ADS; Soares IF; Rodrigues-da-Silva RN; Rodolphi CM; Albrecht L; Donassolo RA; Lopez-Camacho C; Ano Bom APD; Neves PCDC; Conte FP; Pratt-Riccio LR; Daniel-Ribeiro CT; Totino PRR; Lima-Junior JDC
    Front Immunol; 2024; 15():1392043. PubMed ID: 38962015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
    Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
    Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge.
    Hutchings CL; Birkett AJ; Moore AC; Hill AV
    Infect Immun; 2007 Dec; 75(12):5819-26. PubMed ID: 17908809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections.
    Whitacre DC; Espinosa DA; Peters CJ; Jones JE; Tucker AE; Peterson DL; Zavala FP; Milich DR
    PLoS One; 2015; 10(5):e0124856. PubMed ID: 25933001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.
    Yadava A; Sattabongkot J; Washington MA; Ware LA; Majam V; Zheng H; Kumar S; Ockenhouse CF
    Infect Immun; 2007 Mar; 75(3):1177-85. PubMed ID: 17158893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-dose viral-vectored
    Yamamoto Y; Fabbri C; Okuhara D; Takagi R; Kawabata Y; Katayama T; Iyori M; Hasyim AA; Sakamoto A; Mizukami H; Shida H; Lopes S; Yoshida S
    Front Immunol; 2024; 15():1372584. PubMed ID: 38745665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
    McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
    Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.